Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TDO2 | P48775 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15145890 | 0.89 | ALDH1A1 (0.77) | ALDH1A1MEN1KMT2APKMCYP3A4 | |
| Hydrochloric Acid SCHEMBL20522373 | 0.84 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2APKMCYP3A4 | |
| SCHEMBL19603054 | 0.84 | CYP3A4 (0.75) | ALDH1A1MEN1KMT2APKMCYP3A4 | |
| SCHEMBL14628032 | 0.82 | CYP3A4 (1.00) | CYP3A4LMNACA1CA2CA9 | |
| SCHEMBL66632 | 0.81 | CYP3A4 (0.70) | ALDH1A1MEN1KMT2ACYP3A4CA1 | |
| SCHEMBL15145875 | 0.81 | CYP3A4 (0.70) | ALDH1A1MEN1KMT2APKMCYP3A4 | |
| SCHEMBL1460880 | 0.81 | CYP3A4 (0.70) | ALDH1A1MEN1KMT2ACYP3A4LMNA | |
| SCHEMBL16638854 | 0.81 | CYP3A4 (0.70) | ALDH1A1MEN1KMT2APKMCYP3A4 | |
| SCHEMBL16093341 | 0.81 | CYP3A4 (0.70) | ALDH1A1MEN1KMT2APKMCYP3A4 | |
| Hydrochloric Acid SCHEMBL28522062 | 0.81 | CYP3A4 (0.96) | CYP3A4LMNACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3483166-B1 | IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | KOREA INST SCI & TECH (KR) | 2023-11-01 | — | — | EP | disclosed |
| CN-115974723-A | Carboxamide ethylene anthracenes compound, pharmaceutical composition containing same and application thereof | 中国药科大学 | 2023-04-18 | — | — | CN | disclosed |
| US-11332479-B2 | Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-05-17 | — | — | US | disclosed |
| CN-109689659-B | Imidazooxazole derivative having anti-tumor effect and pharmaceutical composition comprising the same | 韩国科学技术研究院 | 2022-01-28 | — | — | CN | disclosed |
| CN-113121564-A | Imidazooxazole derivative having anti-tumor effect and pharmaceutical composition comprising the same | 韩国科学技术研究院 | 2021-07-16 | — | — | CN | disclosed |
| EP-3845539-A1 | IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Korea Institute of Science and Technology (KR) | 2021-07-07 | — | — | EP | disclosed |
| US-20200131199-A1 | IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-04-30 | — | — | US | disclosed |
| US-10570155-B2 | Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-02-25 | — | — | US | disclosed |
| US-20190211032-A1 | IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2019-07-11 | — | — | US | disclosed |
| EP-3483166-A1 | IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Korea Institute of Science and Technology (KR) | 2019-05-15 | — | — | EP | disclosed |
| CN-104220058-A | Serine racemase inhibitor | NAT UNIV CORP UNIV TOYAMA | 2014-12-17 | — | — | CN | disclosed |
| EP-2808014-A1 | SERINE RACEMASE INHIBITOR | National University Corporation University Of Toyama (JP) | 2014-12-03 | — | — | EP | disclosed |
| EP-2808014-A1 | SERINE RACEMASE INHIBITOR | National University Corporation University Of Toyama (JP) | 2014-12-03 | — | — | EP | disclosed |
| WO-2013111798-A1 | SERINE RACEMASE INHIBITOR | 国立大学法人 富山大学 (JP) | 2013-08-01 | — | — | WO | disclosed |
| US-5585392-A | TREATING OR PREVENTING STROKES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-12-17 | — | — | US | disclosed |
| US-5506246-A | Method for treating depression using substituted aminomethyltetralins and their heterocyclic analogues | BAYER AKTIENGESELLSCHAFT (DE) | 1996-04-09 | — | — | US | disclosed |
| EP-0352613-B1 | Substituted amino methyl tetralines, and their heterocyclic analogous compounds | BAYER AG (DE) | 1994-04-20 | — | — | EP | disclosed |
| US-5300523-A | Binding serotonin receptors, treating nervous system disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1994-04-05 | — | — | US | disclosed |
| US-5137901-A | For binding 5-HT 1 receptors; treating central nervous system disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-11 | — | — | US | disclosed |
| EP-0352613-A2 | Substituted amino methyl tetralines, and their heterocyclic analogous compounds | BAYER AG (DE) | 1990-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131199-A1 | IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | TPMT, MYD88, IDO1 | ALDH1A1 1785/4885MEN1 1008/4885KMT2A 675/4885 |
| US-10570155-B2 | Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same | TPMT, MYD88, IDO1 | ALDH1A1 1785/4885MEN1 1008/4885KMT2A 675/4885 |
| US-11332479-B2 | Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same | TPMT, MYD88, IDO1 | ALDH1A1 1785/4885MEN1 1008/4885KMT2A 675/4885 |
| US-20190211032-A1 | IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | TPMT, MYD88, IDO1 | ALDH1A1 1785/4885MEN1 1008/4885KMT2A 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.